PMID- 27424010
OWN - NLM
STAT- MEDLINE
DCOM- 20170117
LR  - 20181202
IS  - 1735-9694 (Electronic)
IS  - 0044-6025 (Linking)
VI  - 54
IP  - 7
DP  - 2016 Jul
TI  - Effects of DHA Supplementation on Vascular Function, Telomerase Activity in PBMC, 
      Expression of Inflammatory Cytokines, and PPARgamma-LXRalpha-ABCA1 Pathway in Patients 
      With Type 2 Diabetes Mellitus: Study Protocol for Randomized Controlled Clinical 
      Trial.
PG  - 410-7
AB  - Docosahexaenoic acid (DHA), as an omega-3 fatty acid, in a natural ligand of 
      peroxisome proliferator-activated receptors (PPARs). Regarding the combinative 
      effects of Nutrigenomics and Nutrigenetics and due to the lack of in vivo studies 
      conducted using natural ligands of PPARs, we aimed to evaluate the effects of DHA 
      supplementation on vascular function, telomerase activity, and PPARgamma-LXRalpha-ABCA1 
      pathway, in patients with type 2 diabetes mellitus (T2DM), based on the Pro12Ala 
      polymorphism in PPARgamma encoding gene. 72 T2DM patients (36 dominant and 36 
      recessive allele carriers), aged 30-70, with body mass index of 18.5 to 35 kg/m2, 
      will be participated in this double blind randomized controlled trial. In each 
      group, stratification will be performed based on sex and age and participants 
      will be randomly assigned to receive 2.4 g/day DHA or placebo (paraffin) for 8 
      weeks. PPARgamma genotyping will be carried out using PCR-RFLP method; Telomerase 
      activity will be estimated by PCR-ELISA TRAP assay; mRNA expression levels of 
      target genes will be assessed using real time PCR. Serum levels of ADMA, sCD163 
      and adiponectin, will be measured using ELISA commercial kits. The present study 
      is designed in order to help T2DM patients to modify their health conditions 
      based on their genetic backgrounds, and to recommend the proper food ingredients 
      as the natural agonists for PPARs in order to prevent and treat metabolic 
      abnormalities of the disease.
FAU - Toupchian, Omid
AU  - Toupchian O
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Sotoudeh, Gity
AU  - Sotoudeh G
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Mansoori, Anahita
AU  - Mansoori A
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. AND Nutrition 
      and Metabolic Diseases Research Center, Jundishapur University of Medical 
      Sciences, Ahvaz, Iran.
FAU - Djalali, Mahmoud
AU  - Djalali M
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Keshavarz, Seyyed Ali
AU  - Keshavarz SA
AD  - Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Nasli-Esfahani, Ensieh
AU  - Nasli-Esfahani E
AD  - Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Alvandi, Ehsan
AU  - Alvandi E
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Koohdani, Fariba
AU  - Koohdani F
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. AND Diabetes 
      Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Iran
TA  - Acta Med Iran
JT  - Acta medica Iranica
JID - 14540050R
RN  - 0 (ABCA1 protein, human)
RN  - 0 (ATP Binding Cassette Transporter 1)
RN  - 0 (Cytokines)
RN  - 0 (Liver X Receptors)
RN  - 0 (PPAR gamma)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - ATP Binding Cassette Transporter 1/metabolism
MH  - Adult
MH  - Aged
MH  - Cytokines/*metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Docosahexaenoic Acids/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Liver X Receptors/metabolism
MH  - Male
MH  - Middle Aged
MH  - PPAR gamma/metabolism
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Genetic
MH  - Polymorphism, Restriction Fragment Length
MH  - Signal Transduction/*drug effects
MH  - Telomerase/*drug effects
OTO - NOTNLM
OT  - ADMA
OT  - Docosahexaenoic acid
OT  - Telomerase activity
OT  - Type 2 diabetes mellitus
OT  - sCD163
EDAT- 2016/07/18 06:00
MHDA- 2017/01/18 06:00
CRDT- 2016/07/18 06:00
PHST- 2016/07/09 00:00 [accepted]
PHST- 2016/07/18 06:00 [entrez]
PHST- 2016/07/18 06:00 [pubmed]
PHST- 2017/01/18 06:00 [medline]
PST - ppublish
SO  - Acta Med Iran. 2016 Jul;54(7):410-7.